Drugs / Ridinilazole
Ridinilazole
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02784002 | Dec 2014 → Aug 2016 | Clostridium infectious disease | Summit Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02092935 | Apr 2014 → Oct 2015 | Clostridium difficile colitis | Summit Therapeutics | Completed | Met primary |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT04802837 | May → Sep 2021 | Clostridium infectious disease | Summit Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT03595553 | Jan 2019 → Nov 2021 | Clostridium infectious disease | Summit Therapeutics | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ridinilazole | “ridinilazole (SMT19969) and vancomycin” PMID 29718329 ↗ Aug 2018 |
| Known as | Ridinilazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3753858 ↗ |
| Known as | SMT19969 | “Ridinilazole (SMT19969)” NCT02784002 ↗ |
| Modality | Small molecule | — CHEMBL3753858 ↗ |